Featured Articles

With a view to addressing a $1.8 billion market globally, and a European market estimated to exceed $500 million, TechCare Corporation a technology company with a revolutionary delivery…
Read More...

Late-stage clinical biopharmaceutical company, Liquidia Technologies focused on enhancing the performance of medicine by precisely engineering drug particles, today announced positive…
Read More...

COMPASS Trial results suggest affirmative Penumbra;s approach to effective thrombectomy approach for acute ischemic stroke as part of the ADAPT (A DirectAspiration, First Pass …
Read More...

Japan's Ministry of health, labor and Welfare extended marketing and manufacturing authorization for Regeneron's DUPIXENT for the treatment of atopic dermatitis in adults not curbed by…
Read More...

Swedish Orphan Biovitrum AB confirmed FDA's acceptance of the investigational new drug application for the drug candidate SOBI003 along with granting Fast track status to it. SOBI003 is…
Read More...

Surefire Medical affirmed the appointment of Mary T. Szela as its CEO, President and a member of the company's Board Of Directors. James Chomas PhD precedes Szela who served as…
Read More...

Puma Biotechnology asserted that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has conveyed a negative trend vote after discussions…
Read More...

Cerus Corporation asserted successful achievement of primary efficacy and safety endpoints in the Company's Phase 3 transfusion study of Chronic anaemia assessing INTERCEPT-treated Red…
Read More...

Celgene Corporation and Juno Therapeutics signed a definitive merger agreement in which Celgene has initiated acquisition of Juno Therapeutics. As per the terms of the agreement, …
Read More...

Astellas Pharma and Vical asserted the negative results for Phase 3 Helios Clinical Trial for ASP0113, an investigational DNA vaccine being developed for cytomegalovirus…
Read More...

Immuno-oncology company, Agenus asserted the launch of its proprietary anti- CTLA4 (AGEN1884) and anti-PD1 (AGEN2034) antibodies. The open-label Phase 1/2 study is designed to evaluate…
Read More...

Amgen affirms optimistic outcomes for Phase 3b LIBERTY study evaluating the efficacy and safety of Aimovig (erenumab) 140 mg in patients with episodic migraine who had experienced two…
Read More...

AstraZeneca and Merck asserted the sanctioning of LYNPARZA tablets for patients with platinum-sensitive relapsed ovarian cancer, regardless of their BRCA mutation status, who responded…
Read More...

Company developing intratumoral cancer immunotherapies, OncoSec Medical claimed the observations of preliminary Clinical trial study related to its OMS-1140 ImmunoPulse 1L-12 in…
Read More...

Privately-held start-up developing VasQ, Laminate Medical Technologies declared the roll- out of its FDA pivotal study in the US. VasQ is an implanted blood vessel external support…
Read More...

Molecule discovery specialist X-Chem, proclaimed a remarkable extension of their present drug discovery collaboration with AstraZeneca. The agreement focuses on the synthesis and…
Read More...

Eiger Biopharmaceuticals displaying forte in development and commercialization of targeted therapies for rare diseases declared negative results for Phase 2 LIBERTY study in pulmonary…
Read More...

Marina Biotech, a biopharmaceutical company committed to the development and commercialization of advanced therapeutics for hypertension, arthritis, pain and oncology embarked on a…
Read More...

US Food and Drug Administration (FDA) has assured priority review of Novartis supplemental Biological License Application (sBLA) for Kymriah suspension for intravenous infusion,…
Read More...

Neurim Pahrmaceuticals and BIOCODEX undertake a license agreement that enlists the fact that BIOCODEX will possess the exclusive marketing rights to market Neurim's Rx paediatric…
Read More...